{
  "docId": "019de076-b8a1-76db-a88b-3941d3b29d31",
  "docSlug": "785649d6ad3bf1f87bd264132bed44c1",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 25,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Includes a biological pathway diagram and a dose-response curve showing target validation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/7",
  "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31",
  "deckJsonHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31.json",
  "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.58,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Target validation: The GCN2 inhibitor A92 antagonizes the antiproliferative effect of NXP800 in ARID1a- mutated SKOV3 cells (approx. 50-fold change in GI50). Powers et al., AACR 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05f44e23-bdef-45b3-9118-a9150786fbd1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.58,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Cell proliferation vs NXP800 concentration showing NXP800 efficacy and reversal by GCN2 inhibitor A92.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c49fc3c5-1688-4827-8876-0152023c5df2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.5,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "image",
      "text": "Biological pathway diagram showing GCN2 activation, eIF2a phosphorylation, and ATF4 translation leading to cell death.",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cef49233-877e-4439-95ce-399630cc64c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.23,
        "y": 0.78
      },
      "kind": "list",
      "text": "Inhibition of cap-dependent translation and chronic activation of the integrated stress response (ISR) -> Cancer cell death. ARID1a-mutated tumors display an increased dependence on translation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "105da90d-f89c-44e9-b2bf-ddca25f33fab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.038,
        "y": 0.06
      },
      "kind": "title",
      "text": "NXP800 Mechanism of Action",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca60dd5c-519b-4b5d-b854-89896dd95a8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.038,
        "y": 0.12
      },
      "kind": "title",
      "text": "NXP800 is a GCN2 kinase activator",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae493a53-9fd4-43ee-b983-63a13df443ef",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "5b56f346-6abf-4276-b8b7-2205ea3045b4",
      "evidence": "chart/line: Cell proliferation vs NXP800 concentration showing NXP800 efficacy and reversal by GCN2 inhibitor A92.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "40349491-57b9-4003-8fec-4f377afe6109",
      "evidence": "The diagram illustrates the sequential biological steps from NXP800 activation to cell death.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 7,
      "beatId": "816636d5-21da-498e-b716-dab6ea2ab36b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Mechanism of Action and clinical results for NXP800",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431",
      "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts",
      "position": 0,
      "objective": "Highlight the need for new cancer treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}